94-31200. Schedules of Controlled Substances; Extension of Temporary Placement of 4-Bromo-2,5-dimethoxyphenethyl- amine in Schedule I  

  • [Federal Register Volume 59, Number 244 (Wednesday, December 21, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-31200]
    
    
    [[Page Unknown]]
    
    [Federal Register: December 21, 1994]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF JUSTICE
    
    Drug Enforcement Administration
    
    21 CFR Part 1308
    
    [DEA--127E]
    
     
    
    Schedules of Controlled Substances; Extension of Temporary 
    Placement of 4-Bromo-2,5-dimethoxyphenethyl- amine in Schedule I
    
    AGENCY: Drug Enforcement Administration, Justice.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: This final rule is issued by the Deputy Administrator of the 
    Drug Enforcement Administration (DEA) to extend the temporary 
    scheduling of 4-bromo-2,5-dimethoxyphenethylamine (4-bromo-2,5-DMPEA) 
    in Schedule I of the Controlled Substances Act (CSA). The temporary 
    scheduling of 4-bromo-2,5-DMPEA is due to expire on January 6, 1995. 
    This notice will extend the temporary scheduling of 4-bromo-2,5-DMPEA 
    for six months or until rule making proceeding are completed, whichever 
    occurs first.
    
    EFFECTIVE DATE: January 6, 1995.
    
    FOR FURTHER INFORMATION CONTACT:Howard McClain, Jr., Chief, Drug and 
    Chemical Evaluation Section, Drug Enforcement Administration, 
    Washington, DC 20537, Telephone: (202) 307-7183.
    
    SUPPLEMENTARY INFORMATION: On January 6, 1994, the Acting Administrator 
    of the DEA published a final rule in the Federal Register (59 FR 671) 
    amending Sec. 1308.11(g) of Title 21 of the Code of Federal Regulations 
    to temporarily place 4-bromo-2,5-DMPEA into Schedule I of the CSA 
    pursuant to the temporary scheduling provisions of 21 U.S.C. 811(g). 
    This final rule, which became effective on the date of publication, was 
    based on findings by the Acting Administrator that the temporary 
    scheduling of 4-bromo-2,5-DMPEA was necessary to avoid an imminent 
    hazard to the public safety. Section 201(h)(2) of the CSA (21 U.S.C. 
    811(h)(2)) requires that the temporary scheduling of a substance 
    expires at the end of one year from the effective date of the order. 
    However, during the pendency of proceedings under 21 U.S.C. 811(a)(1) 
    with respect to the substance, temporary scheduling of that substance 
    may be extended for up to six months. Proceedings for the scheduling of 
    a substance under 21 U.S.C. 811(a) may be initiated by the Attorney 
    General (delegated to the Administrator of the DEA pursuant to 28 CFR 
    0.100 and redelegated to the Deputy Administrator pursuant to 28 CFR 
    0.104) on his own motion, at the request of the Secretary of Health and 
    Human Services, or on the petition of any interested party. Such 
    proceedings regarding 4-bromo-2,5-DMPEA has been initiated by the 
    Deputy Administrator.
        Therefore, the temporary scheduling of 4-bromo-2,5-DMPEA, which is 
    due to expire on January 6, 1995, may be extended until July 6, 1995, 
    or until proceedings initiated in accordance with 21 U.S.C. 811(a) are 
    completed, whichever occurs first. Pursuant to U.S.C. 811(h)(2) the 
    Deputy Administrator hereby orders that the temporary scheduling of 4-
    bromo-2,5-DMPEA be extended until July 6, 1995, or until the conclusion 
    of scheduling proceedings initiated in accordance with 21 U.S.C. 
    811(a), whichever occurs first.
        The Deputy Administrator of the DEA hereby certifies that extension 
    of the temporary placement of 4-bromo-2,5-DMPEA in Schedule I of the 
    CSA will have no significant impact upon entities whose interests must 
    be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et 
    seq. This action involves the extension of temporary control of a 
    substance with no currently accepted medical use in the United States.
        The six month extension of 4-bromo-2,5-DMPEA in Schedule I of the 
    CSA is not a significant regulatory action for the purposes of 
    Executive Order (E.O.) 12866 of September 30, 1993. Drug scheduling 
    matters are not subject to review by the Office of Management and 
    Budget (OMB) pursuant to the provisions of E.O. 12866, Sec. 3(d)(1). 
    This regulation responds to an emergency situation posing no imminent 
    hazard to the public safety and is essential to criminal law 
    enforcement function of the United States.
        This action has been analyzed in accordance with the principles and 
    criteria in Executive Order 12612, and it has been determined that this 
    final rule does not have sufficient federalism implications to warrant 
    the preparation of a Federalism Assessment.
    
        Dated: December 9, 1994.
    Stephen H. Greene,
    Deputy Administrator.
    [FR Doc. 94-31200 Filed 12-20-94; 8:45 am]
    BILLING CODE 4410-09-M
    
    
    

Document Information

Published:
12/21/1994
Department:
Drug Enforcement Administration
Entry Type:
Uncategorized Document
Action:
Final rule.
Document Number:
94-31200
Dates:
January 6, 1995.
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: December 21, 1994, DEA--127E
CFR: (1)
21 CFR 1308